The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Self-screening questionnaire for perianal fistulizing disease in patients with Crohn's disease

  • O Seong Kweon (Division of Gastroenterology, Department of Internal Medicine, Kyungpook National University, School of Medicine) ;
  • Ben Kang (Department of Pediatrics, Kyungpook National University, School of Medicine) ;
  • Yoo Jin Lee (Division of Gastroenterology, Department of Internal Medicine, Keimyung University School of Medicine) ;
  • Eun Soo Kim (Division of Gastroenterology, Department of Internal Medicine, Kyungpook National University, School of Medicine) ;
  • Sung Kook Kim (Division of Gastroenterology, Department of Internal Medicine, Kyungpook National University, School of Medicine) ;
  • Hyun Seok Lee (Division of Gastroenterology, Department of Internal Medicine, Kyungpook National University, School of Medicine) ;
  • Yun Jin Chung (Division of Gastroenterology, Department of Internal Medicine, Kyungpook National University, School of Medicine) ;
  • Kyeong Ok Kim (Division of Gastroenterology, Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Byung Ik Jang (Division of Gastroenterology, Department of Internal Medicine, Yeungnam University College of Medicine)
  • Received : 2023.09.27
  • Accepted : 2023.12.19
  • Published : 2024.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background/Aims: A poor prognostic factor for Crohn's disease (CD) includes perianal fistulizing disease, including perianal fistula and/or perianal abscess. Currently, a tool to assess perianal symptoms in patients with CD remains nonexistent. This study aimed to develop a perianal fistulizing disease self-screening questionnaire for patients with CD. Methods: This prospective pilot study was conducted at three tertiary referral centers between January 2019 and May 2020. We formulated questions on perianal symptoms, including tenesmus, anal discharge, bleeding, pain, and heat. A 4-point Likert scale was used to rate each question. Patients with CD completed a questionnaire and underwent pelvic magnetic resonance imaging (MRI). Results: Overall, 93 patients were enrolled, with 51 (54.8%) diagnosed with perianal fistulizing disease, as determined by pelvic MRI. The Spearman correlation findings demonstrated that anal pain (p = 0.450, p < 0.001) and anal discharge (p = 0.556, p < 0.001) were the symptoms that most significantly correlated with perianal disease. For anal pain and discharge, the area under the receiver operating characteristic curve of the scores was significantly higher than that of the combined score for all five symptoms (0.855 vs. 0.794, DeLong's test p = 0.04). For the two symptoms combined, the sensitivity, specificity, and positive predictive and negative predictive values were 88.2, 73.8, 80.4, and 83.8%, respectively, with 81.7% accuracy for detecting perianal fistulizing disease. Conclusions: This study indicates that simple questions regarding anal pain and discharge can help accurately identify the presence of perianal fistulizing disease in patients with CD.

Keywords

Acknowledgement

This work was supported by a Biomedical Research Institute grant of Kyungpook National University Hospital (2021).

References

  1. Wewer MD, Zhao M, Nordholm-Carstensen A, Weimers P, Seidelin JB, Burisch J. The incidence and disease course of perianal Crohn's disease: a Danish nationwide cohort study, 1997-2015. J Crohns Colitis 2021;15:5-13. https://doi.org/10.1093/ecco-jcc/jjaa118
  2. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. Dis Mon 2018;64:20-57. https://doi.org/10.1016/j.disamonth.2017.07.001
  3. Shi HY, Levy AN, Trivedi HD, Chan FKL, Ng SC, Ananthakrishnan AN. Ethnicity influences phenotype and outcomes in inflammatory bowel disease: a systematic review and meta-analysis of population-based studies. Clin Gastroenterol Hepatol 2018;16:190-197.e11. https://doi.org/10.1016/j.cgh.2017.05.047
  4. Kaur M, Dalal RL, Shaffer S, Schwartz DA, Rubin DT. Inpatient management of inflammatory bowel disease-related complications. Clin Gastroenterol Hepatol 2020;18:1346-1355. https://doi.org/10.1016/j.cgh.2019.12.040
  5. Adegbola SO, Dibley L, Sahnan K, et al. Burden of disease and adaptation to life in patients with Crohn's perianal fistula: a qualitative exploration. Health Qual Life Outcomes 2020;18:370.
  6. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405. https://doi.org/10.1056/NEJM199905063401804
  7. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010;32:1228-1239. https://doi.org/10.1111/j.1365-2036.2010.04466.x
  8. Panes J, Rimola J. Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol 2017;14:652-664. https://doi.org/10.1038/nrgastro.2017.104
  9. Meima-van Praag EM, van Rijn KL, et al. Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial. Lancet Gastroenterol Hepatol 2022;7:617-626. https://doi.org/10.1016/S2468-1253(22)00088-7
  10. Badla O, Goit R, Saddik SE, et al. The multidisciplinary management of perianal fistulas in Crohn's disease: a systematic review. Cureus 2022;14:e29347.
  11. Laland M, Francois M, D'Amico F, et al. Identification of the optimal medical and surgical management for patients with perianal fistulising Crohn's disease. Colorectal Dis 2023;25:75-82. https://doi.org/10.1111/codi.16314
  12. Ye BD, Jang BI, Jeen YT, Lee KM, Kim JS, Yang SK; IBD Study Group of the Korean Association of the Study of Intestinal Diseases. [Diagnostic guideline of Crohn's disease]. Korean J Gastroenterol 2009;53:161-176. Korean.
  13. Koh SJ, Hong SN, Park SK, et al.; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease. Intest Res 2023;21:43-60. https://doi.org/10.5217/ir.2022.00029
  14. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753. https://doi.org/10.1136/gut.2005.082909
  15. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
  16. Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 2013;7:556-585. https://doi.org/10.1016/j.crohns.2013.02.020
  17. Steinhart AH, Panaccione R, Targownik L, et al. Clinical practice guideline for the medical management of perianal fistulizing Crohn's disease: the Toronto consensus. Inflamm Bowel Dis 2019;25:1-13. https://doi.org/10.1093/ibd/izy247
  18. Juncadella AC, Alame AM, Sands LR, Deshpande AR. Perianal Crohn's disease: a review. Postgrad Med 2015;127:266-272. https://doi.org/10.1080/00325481.2015.1023160
  19. Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg 2018;126:1763-1768. https://doi.org/10.1213/ANE.0000000000002864
  20. Atia O, Focht G, Lujan R, et al. Perianal Crohn disease is more common in children and is associated with complicated disease course despite higher utilization of biologics: a population-based study from the epidemiology group of the Israeli IBD Research Nucleus (epiIIRN). J Pediatr Gastroenterol Nutr 2022;74:788-793. https://doi.org/10.1097/MPG.0000000000003422
  21. Allan A, Linares L, Spooner HA, Alexander-Williams J. Clinical index to quantitate symptoms of perianal Crohn's disease. Dis Colon Rectum 1992;35:656-661. https://doi.org/10.1007/BF02053756
  22. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27-32. https://doi.org/10.1097/00004836-199501000-00008
  23. Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn disease: a new scoring system to evaluate and predict outcome of surgical intervention. Arch Surg 2002;137:774-777; discussion 778. https://doi.org/10.1001/archsurg.137.7.774
  24. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-880. https://doi.org/10.1053/gast.2002.32362
  25. Gecse KB, Sebastian S, Hertogh Gd, et al. Results of the fifth scientific workshop of the ECCO [II]: clinical aspects of perianal fistulising Crohn's disease-the unmet needs. J Crohns Colitis 2016;10:758-765. https://doi.org/10.1093/ecco-jcc/jjw039
  26. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005;48:1416-1423. https://doi.org/10.1007/s10350-005-0052-6
  27. Barreiro Dominguez EM, Vazquez-Garcia I, Perez-Corbal L, Ballinas Miranda JR, Antelo JS, Parajo Calvo A. Mesenchymal stem cells for the treatment of perianal fistulizing Crohn's disease-a video vignette. Colorectal Dis 2022;24:1441-1442. https://doi.org/10.1111/codi.16206
  28. Tanaka S, Matsuo K, Sasaki T, et al. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed? Hepatogastroenterology 2010;57:3-7.